pH-mediated potentiation of aminoglycosides kills bacterial persisters and eradicates in vivo biofilms

Journal of Infectious Diseases

Volumn 210, Issue 9, 2014, Pages 1357-1366

  Lebeaux, David ^a   Chauhan, Ashwini ^a   Létoffé, Sylvie ^a   Fischer, Frédéric ^a   De Reuse, Hilde ^a   Beloin, Christophe ^a   Ghigo, Jean Marc ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Aminoglycoside; Biofilm; Catheter related infections; Persister; Proton motive force

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ARGININE; GENTAMICIN; HISTIDINE; LYSINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ALKALINIZATION; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOPLANKTON; BIOFILM; CATHETER INFECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERSISTENT INFECTION; PH; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; STAPHYLOCOCCUS AUREUS; ADVERSE EFFECTS; ANIMAL; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETER; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; ESCHERICHIA COLI INFECTIONS; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; ARGININE; BIOFILMS; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETERS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENTAMICINS; HYDROGEN-ION CONCENTRATION; IN VITRO TECHNIQUES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84922041653     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu286     Document Type: Article

References (40)

1. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15:167-93.
2. Arciola CR, Montanaro L, Costerton JW. New trends in diagnosis and control strategies for implant infections. Int J Artif Organs 2011; 34:727-36.
3. Lewis K. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 2008; 322:107-31.
4. Fey PD. Modality of bacterial growth presents unique targets: how do we treat biofilm-mediated infections? Curr Opin Microbiol 2010; 13:610-5.
5. Yang L, Liu Y, Wu H, et al. Combating biofilms. FEMS Immunol Med Microbiol 2012; 65:146-57.
6. O'Toole GA. Microbiology: Jekyll or hide? Nature 2004; 432:680-1.
7. Allison KR, Brynildsen MP, Collins JJ. Heterogeneous bacterial persisters and engineering approaches to eliminate them. Curr Opin Microbiol 2011; 14:593-8.
8. Conlon BP, Nakayasu ES, Fleck LE, et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 2013; 503:365-70.
9. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 2011; 473:216-20.
10. Sabath LD, Toftegaard I. Rapid microassays for clindamycin and gentamicin when present together and the effect of pH and of each on the antibacterial activity of the other. Antimicrob Agents Chemother 1974; 6:54-9.
11. Schlessinger D. Failure of aminoglycoside antibiotics to kill anaerobic, low-pH, and resistant cultures. Clin Microbiol Rev 1988; 1:54-9.
12. Létoffé S, Audrain B, Bernier S, Delepierre D, Ghigo JM. Aerial exposure to the bacterial volatile compound trimethylamine modifies antibiotic resistance of physically separated bacteria by raising medium pH. MBio 2013; 5:e00944-13.
13. Moriarty TF, Elborn JS, Tunney MM. Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates. Br J Biomed Sci 2007; 64:101-4.
14. Bernier C, Gounon P, Le Bouguenec C. Identification of an aggregative adhesion fimbria (AAF) type III-encoding operon in enteroaggregative Escherichia coli as a sensitive probe for detecting the AAF-encoding operon family. Infect Immun 2002; 70:4302-11.
15. Foucault ML, Thomas L, Goussard S, Branchini BR, Grillot-Courvalin C. In vivo bioluminescence imaging for the study of intestinal colonization by Escherichia coli in mice. Appl Environ Microbiol 2010; 76:264-74.
16. Ramphal R, Balloy V, Jyot J, Verma A, Si-Tahar M, Chignard M. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J Immunol 2008; 181: 586-92.
17. Sun M, Wartel M, Cascales E, Shaevitz JW, Mignot T. Motor-driven intracellular transport powers bacterial gliding motility. Proc Natl Acad Sci U S A 2011; 108:7559-64.
18. Chauhan A, Lebeaux D, Decante B, et al. A rat model of central venous catheter to study establishment of long-term bacterial biofilm and related acute and chronic infections. PLoS One 2012; 7:e37281.
19. Van Praagh AD, Li T, Zhang S, et al. Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infections. Antimicrob Agents Chemother 2011; 55:4081-9.
20. Zuluaga AF, Agudelo M, Cardeno JJ, Rodriguez CA, Vesga O. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PloS One 2010; 5: e10744.
21. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 2004; 230:13-8.
22. Taber HW, Mueller JP, Miller PF, Arrow AS. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev 1987; 51:439-57.
23. Spoering AL, Lewis K. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol 2001; 183:6746-51.
24. Chauhan A, Lebeaux D, Ghigo JM, Beloin C. Full and broad-spectrum in vivo eradication of catheter-associated biofilms using gentamicin- EDTA antibiotic lock therapy. Antimicrob Agents Chemother 2012; 56:6310-8.
25. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45.
26. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-22.
27. Mates SM, Eisenberg ES, Mandel LJ, Patel L, Kaback HR, Miller MH. Membrane potential and gentamicin uptake in Staphylococcus aureus. Proc Natl Acad Sci U S A 1982; 79:6693-7.
28. Bernier SP, Ha DG, Khan W, Merritt JH, O'Toole GA. Modulation of Pseudomonas aeruginosa surface-associated group behaviors by individual amino acids through c-di-GMP signaling. Res Microbiol 2011; 162:680-8.
29. Zhu Y,Weiss EC, Otto M, Fey PD, Smeltzer MS, Somerville GA. Staphylococcus aureus biofilm metabolism and the influence of arginine on polysaccharide intercellular adhesin synthesis, biofilm formation, and pathogenesis. Infect Immun 2007; 75:4219-26.
30. Borriello G, Richards L, Ehrlich GD, Stewart PS. Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Chemother 2006; 50:382-4.
31. Stewart PS, Franklin MJ. Physiological heterogeneity in biofilms. Nat Rev Microbiol 2008; 6:199-210.
32. Banning AP, Prendergast B. Intravenous L-arginine reduces VE/VCO2 slope acutely in patients with severe chronic heart failure. Eur J Heart Fail 1999; 1:187-90.
33. Miller HI, Dascalu A, Rassin TA, Wollman Y, Chernichowsky T, Iaina A. Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, doubleblind clinical trial. Am J Nephrol 2003; 23:91-5.
34. Adler A, Yaniv I, Steinberg R, et al. Infectious complications of implantable ports and Hickman catheters in paediatric haematology-oncology patients. J Hosp Infect 2006; 62:358-65.
35. Lebeaux D, Larroque B, Gellen-Dautremer J, et al. Clinical outcome after a totally implantable venous access port-related infection in cancer patients: a prospective study and review of the literature. Medicine 2012; 91:309-18.
36. Fernandez-Hidalgo N, Almirante B, Calleja R, et al. Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J Antimicrob Chemother 2006; 57:1172-80.
37. Lebeaux D, Fernandez-Hidalgo N, Chauhan A, et al. Management of infections related to totally implantable venous-access ports: challenges and perspectives. Lancet Infect Dis 2014; 14:146-59.
38. Erdogan-Yildirim Z, Burian A, Manafi M, Zeitlinger M. Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine. Res Microbiol 2011; 162:249-52.
39. Irwin NJ, McCoy CP, Carson L. Effect of pH on the in vitro susceptibility of planktonic and biofilm-grown Proteus mirabilis to the quinolone antimicrobials. J Appl Microbiol 2013; 115:382-9.
40. Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011; 9:32.